Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial
Publication Type:
Journal Article
Authors:
M S Sulkowski;
Eron, J.J.;
D L Wyles;
Trinh, R.;
Lalezari, J.;
Wang, C.;
Slim, J.;
Bhatti, L.;
Gathe, J.;
P J Ruane;
Elion, R.;
Bredeek, F.;
Brennan, R.;
Blick, G.;
Khatri, A.;
Gibbons, K.;
Hu, Y.B.;
Fredrick, L.;
Schnell, G.;
Pilot-Matias, T.;
Tripathi, R.;
Da Silva-Tillmann, B.;
McGovern, B.;
Campbell, A.L.;
Podsadecki, T.Source:
JAMA, Volume 313, Issue 12, p.1223-1231 (2015)
Keywords:
Adult,
AIDS,
Antiretroviral,
atazanavir,
Baltimore,
California,
Chicago,
co-infected,
co-infection,
coinfection,
Connecticut,
Disease,
Disease Progression,
Fatigue,
Genotype,
genotype 1,
HCV,
Headache,
Health,
hepatitis,
Hepatitis C,
hepatitis C virus,
history,
Hiv,
Hiv-1,
Human,
Illinois,
Infection,
interventions,
Liver,
Los Angeles,
Maryland,
Nausea,
New Jersey,
North Carolina,
PART,
Patients,
peginterferon,
Plasma,
Puerto Rico,
Research,
Ribavirin,
Risk,
ritonavir,
Rna,
San Francisco,
sustained virologic response,
SVR,
Texas,
therapy,
toxicity,
treatment,
Treatment Failure,
treatment-naive,
United States,
Universities,
Washington
